PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+21.59%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$852M
AUM Growth
+$852M
(+20%)
Cap. Flow
+$48M
Cap. Flow
% of AUM
5.64%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
31
New
4
Increased
14
Reduced
5
Closed
8
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$36.8M |
| 2 |
Vor Biopharma
VOR
|
$31.5M |
| 3 |
Arcellx
ACLX
|
$27.3M |
| 4 |
Biogen
BIIB
|
$23.3M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$22.1M |
Top Sells
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$80.1M |
| 2 |
Axsome Therapeutics
AXSM
|
$23.2M |
| 3 |
Ascendis Pharma
ASND
|
$17.7M |
| 4 |
Akero Therapeutics
AKRO
|
$12.5M |
| 5 |
Esperion Therapeutics
ESPR
|
$11.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $68.5M | 8.04% | 852,830 +79,748 | +10% | +$6.41M |
|
|
2
Biogen
BIIB
$19.4B
| $66.1M | 7.76% | 238,772 +84,167 | +54% | +$23.3M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $57.5M | 6.74% | 1,267,970 +417,585 | +49% | +$18.9M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $54.3M | 6.38% | 477,585 +126,180 | +36% | +$14.4M |
|
5
Legend Biotech
LEGN
$6.41B
| $52.7M | 6.18% | 1,054,870 -21,721 | -2% | -$1.08M |
|
6
Viridian Therapeutics
VRDN
$1.5B
| $51.2M | 6% | 1,751,167 +114,956 | +7% | +$3.36M |
|
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $49.7M | 5.84% | 1,954,512 +869,370 | +80% | +$22.1M |
|
8
Immunocore
IMCR
$1.62B
| $49M | 5.75% | 857,925 +84,846 | +11% | +$4.84M |
|
|
9
Ascendis Pharma
ASND
$11.8B
| $43.1M | 5.06% | 352,808 -144,539 | -29% | -$17.7M |
|
|
10
Vor Biopharma
VOR
$250M
| $42.8M | 5.03% | 6,442,825 +4,739,180 | +278% | +$31.5M |
|
11
United Therapeutics
UTHR
$13.8B
| $41.4M | 4.86% | 148,892 +8,331 | +6% | +$2.32M |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $36.8M | 4.32% | +286,288 | New | +$36.8M |
|
|
BCYC
13
Bicycle Therapeutics
BCYC
$511M
| $36.5M | 4.29% | 1,233,280 +74,594 | +6% | +$2.21M |
|
14
argenx
ARGX
$43.6B
| $33.9M | 3.98% | 89,556 -741 | -0.8% | -$281K |
|
|
15
Akero Therapeutics
AKRO
$3.74B
| $33.1M | 3.89% | 604,544 -228,721 | -27% | -$12.5M |
|
|
16
Arcellx
ACLX
$3.85B
| $27.3M | 3.21% | +882,101 | New | +$27.3M |
|
|
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $20.9M | 2.45% | +106,210 | New | +$20.9M |
|
18
Arvinas
ARVN
$568M
| $20.5M | 2.41% | 599,599 +315,822 | +111% | +$10.8M |
|
|
ALPN
19
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $17M | 2% | 2,317,634 +102,912 | +5% | +$756K |
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $16.3M | 1.91% | 890,105 +370,849 | +71% | +$6.79M |
|
21
Zai Lab
ZLAB
$3.68B
| $15.8M | 1.86% | +515,274 | New | +$15.8M |
|
|
PSTX
22
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $12.9M | 1.51% | 2,434,816 +364,708 | +18% | +$1.93M |
|
23
Prothena Corp
PRTA
$441M
| $4.52M | 0.53% | 75,000 -160,826 | -68% | -$9.69M |
|
24
TG Therapeutics
TGTX
$4.65B
| – | – | -1,505,479 | Closed | -$8.91M |
|
|
GTHX
25
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – | -884,574 | Closed | -$11M |
|